Business Wire

Media-Telecom Convergence Projects Demo by IBC and TM Forum at Digital Transformation World

Share

TM Forum, the industry association driving digital transformation through collaboration, and IBC, the world’s most influential media, entertainment and technology show, unveiled the details of three joint proof-of-concept Catalyst projects to be demonstrated at Digital Transformation World in Nice, France, May 14-16, 2019.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190513005442/en/

Catalysts are proof-of-concept projects developed collaboratively. These projects bring together companies large and small to create innovate solutions to common challenges demonstrating how this can be achieved leveraging key TM Forum best practices and standards.

These three unique Media-Telecom Convergence Catalyst projects are the first results of IBC and TM Forum’s collaboration aimed at driving open innovation between the telecoms and media industries. Featured among the 32 projects demonstrated at Digital Transformation World, they incorporate some of today’s most complex business and technology challenges today, including 5G, data management, virtual and augmented reality, edge computing, AI and the automation of business processes for regulatory compliance.

The three Media-Telecom Catalysts are:

  • 5G-Enabled Tourism Experience
    This Catalyst explores ways of creating a pop-up network for delivery of high throughput broadcasting to distant points of fiber presence via mmWave connection. The project investigates how to deliver rich and engaging video-based experiences to users exploring an area of the Roman Baths in the UK and allows a mobile device to view a place as it would have been in the past. Champions: Aardman Entertainment, BBC R&D Participants: Bristol University, Cambridge Communications Systems Ltd., Zeetta Networks Ltd.
  • AI Indexing for Regulatory Practice
    This Catalyst is exploring ways to intelligently automate the identification of on-air content using AI in order to measure and report against compliance metrics set by external regulatory bodies, as well as for accurate measurement of internal editorial, creative and technical standards. Champions: Associated Press, Al Jazeera, RTE; Participants: Metaliquid, QCRI, Tech Mahindra, V-Nova
  • Mobile News Gathering Using AI-Powered Compression
    This Catalyst is working to empower newsrooms and journalists through improved intelligence for the mobile reporter in the field and faster time-to-air for both live and pre-recorded content. It leverages AI and techniques for improved bandwidth utilization through advanced compression techniques. Champions: Associated Press, Al Jazeera, RTE; Participant: V-Nova

“The convergence between telecom and media and entertainment has opened up exciting opportunities for our members to work alongside some of the world’s leading media companies to solve pressing business challenges,” said Andy Tiller, Executive Vice President, Collaboration and Innovation, TM Forum. “These three projects truly showcase how the power of collaboration helped find unique real-world solutions to problems faced by both industries – not only transforming businesses but consumer experience as well."

“As the pace of technology disruption and convergence accelerates, the rapid-fire Media-Telco Catalyst model for cross-sector innovation, partnerships and broader digital transformation is already proving a game-changing approach.” said Imran Sroya, Director, IBC. “We are delighted with the progress of the first three Catalyst projects and look forward to showcasing them at Digital Transformation World this month and at IBC in Amsterdam in September.”

Learn more about TM Forum’s Catalyst program at Digital Transformation World in Nice, France, May 14-16, 2019. With a focus on intelligent operations for a 5G world, Digital Transformation World showcases how businesses can seize opportunity and remain competitive in a rapidly evolving digital world. Click here for the latest event agenda: https://dtw.tmforum.org/agenda/

Ends

About TM Forum

TM Forum is an association of over 850-member companies’ customers across 180 countries. We drive collaboration and collective problem-solving to maximize the business success of communication and digital service providers and their ecosystem of suppliers around the world. Today, our focus is on supporting members as they navigate their unique digital transformation journeys, providing practical and proven assets and tools to accelerate execution and platforms to facilitate collaborative problem solving and innovation. Learn more at www.tmforum.org.

About IBC

IBC is the world’s most influential media, entertainment and technology show, attracting 55,000+ attendees from more than 170 countries and combining a highly respected and peer-reviewed conference with an exhibition that showcases 1,700+ leading industry suppliers of state-of-the-art technology. In addition to the world-class exhibition and conference, IBC also encompasses the IBC Daily, IBCTV and IBC365.

IBC365 provides year-round insight and opinion into the hot topics and key trends from leading industry journalists, along with insightful whitepapers, peer reviewed technical papers, highly engaging webinars and an expansive video library.

Contact information

CCgroup PR
Anais Merlin
E: TMForum@ccgrouppr.com
T: +44 203 824 9200

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

bitFlyer Europe and Quazard Partner to Bring First Ever Trading Competition to Botwars Ultimate Trading1.6.2020 07:00:00 EESTPress release

Leading cryptocurrency exchange bitFlyer, is partnering with crypto-trading game developer Quazard, to bring the first ever gamified trading competition to the Botwars Ultimate Trading universe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200531005005/en/ bitFlyer and Quazard bring the first gamified trading competition to the Botwars Ultimate Trading universe (Graphic: Business Wire) The competition, which launches today, allows Botwars players to compete in a free to enter crypto-trading simulator to win real Bitcoin. This is the first trading competition to launch on Botwars, and the only live trading competition of its type. In Botwars Ultimate Trading, players need to build an army of trading robots (each representing a trade) and lead them into battle to conquer the cryptocurrency markets. Botwars is a real-time, gamified currency trading experience where you will learn new trading skills, unlock powerful new tradin

Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time1.6.2020 04:00:00 EESTPress release

Celltrion Group today announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the virus causing COVID-19. The treatment was also able to show improvement in lung lesions to a normal activity level in animal models. The pre-clinical study was conducted in an animal model in collaboration with one of the Korean National Universities, Chungbuk National University College of Medicine. The trial set out to assess the efficacy of two dosage amounts (low and high) for the antiviral antibody treatment. In comparison to the placebo-controlled group, the research team observed improved recovery in terms of clinical symptom scores such as runny nose, cough and body aches, after the first day of treatment. From the fifth day, significant clinical remission was observed. Reverse transcriptase polymerase chain reaction (RT-PCR) measurement and cell culture-based viral diagnosis were used to a

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 21:31:00 EESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the 25th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 15:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom